


Highlights of This Issue 1425

REVIEW

- 1427** **Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics**
Rosie Elizabeth Ann Gutteridge, Mary Ann Ndiaye, Xiaoqi Liu, and Nihal Ahmad

SMALL MOLECULE THERAPEUTICS

- 1436** **An Artificially Designed Interfering lncRNA Expressed by Oncolytic Adenovirus Competitively Consumes OncomiRs to Exert Antitumor Efficacy in Hepatocellular Carcinoma**
 Xiaoya Li, Yinghan Su, Bin Sun, Weidan Ji, Zhangxiao Peng, Yang Xu, Mengchao Wu, and Changqing Su

- 1452** **Dual Carfilzomib and Doxorubicin-Loaded Liposomal Nanoparticles for Synergistic Efficacy in Multiple Myeloma**
Jonathan D. Ashley, Charissa J. Quinlan, Valerie A. Schroeder, Mark A. Suckow, Vincenzo J. Pizzuti, Tanyel Kiziltepe, and Basar Bilgicer

- 1460** **Concomitant Inhibition of PI3K β and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3K β -Selective Inhibitor**
Hélène Bonnevaux, Olivier Lemaitre, Loic Vincent, Mikhail N. Levit, Fanny Windenberger, Frank Halley, Cécile Delorme, Christoph Lengauer, Carlos Garcia-Echeverria, and Angela Virone-Oddos

- 1472** **Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib**
Rowan E. Miller, Rachel Brough, Ilirjana Bajrami, Chris T. Williamson, Simon McDade, James Campbell, Asha Kigozi, Rumana Rafiq, Helen Pemberton, Rachel Natrajan, Josephine Joel, Holly Astley, Claire Mahoney, Jonathan D. Moore, Chris Torrance, John D. Gordan, James T. Webber, Rebecca S. Levin, Kevan M. Shokat, Sourav Bandyopadhyay, Christopher J. Lord, and Alan Ashworth

- 1485** **A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity**
Sophia Hu, Masumi Ueda, Lindsay Stetson, James Ignatz-Hoover, Stephen Moreton, Amit Chakrabarti, Zhiqiang Xia, Goutam Karan, Marcos de Lima, Mukesh K. Agrawal, and David N. Wald

- 1495** **Triptolide Induces Cell Killing in Multidrug-Resistant Tumor Cells via CDK7/RPB1 Rather than XPB or p44**
Jun-Mei Yi, Xia-Juan Huan, Shan-Shan Song, Hu Zhou, Ying-Qing Wang, and Ze-Hong Miao

- 1504** **Targeting I κ B Kinase β /NF- κ B Signaling in Human Prostate Cancer by a Novel I κ B Kinase β Inhibitor CmpdA**
Yanting Zhang, Rena G. Lapidus, Peiyan Liu, Eun Yong Choi, Samusi Adediran, Arif Hussain, Xinghuan Wang, Xuefeng Liu, and Han C. Dan

- 1515** **Src as a Therapeutic Target in Biliary Tract Cancer**
Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, Seock-Ah Im, Tae-You Kim, Do-Youn Oh, and Yung-Jue Bang


- 1525** **The Discovery and Characterization of K-756, a Novel Wnt/ β -Catenin Pathway Inhibitor Targeting Tankyrase**
Ryoko Okada-Iwasaki, Yuichi Takahashi, Yasuo Watanabe, Hiroshi Ishida, Jun-ichi Saito, Ryuichiro Nakai, and Akira Asai

- 1535** **Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells**
Alessia Calgani, Giulia Vignaroli, Claudio Zamperini, Federica Coniglio, Claudio Festuccia, Ernesto Di Cesare, Giovanni Luca Gravina, Claudia Mattei, Flora Vitale, Silvia Schenone, Maurizio Botta, and Adriano Angelucci

- 1545** **Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R**
Klaas de Lint, Jos B. Poell, Hayssam Soueidan, Katarzyna Jastrzebski, Jordi Vidal Rodriguez, Cor Lieftink, Lodewyk F.A. Wessels, and Roderick L. Beijersbergen

- 1557** **Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer**
Fernanda Musa, Amandine Alard, Gizelka David-West, John P. Curtin, Stephanie V. Blank, and Robert J. Schneider

Table of Contents



1568 *In Vitro* and *In Vivo* Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

Paul E. Hughes, Karen Rex, Sean Caenepeel, Yajing Yang, Yihong Zhang, Martin A. Broome, Hue T. Kha, Teresa L. Burgess, Benny Amore, Paula J. Kaplan-Lefko, Jodi Moriguchi, Jonathan Werner, Michael A. Damore, Daniel Baker, Deborah M. Choquette, Jean-Christophe Harmange, Robert Radinsky, Richard Kendall, Isabelle Dussault, and Angela Coxon

1637 PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species

Noel A. Warfel, Alva G. Sainz, Jin H. Song, and Andrew S. Kraft

1648 Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

Prince Awuah, Tapan K. Bera, Messan Folivi, Oleg Chertov, and Ira Pastan

LARGE MOLECULE THERAPEUTICS

1580 LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence

Xing Gong, Ali Azhdarinia, Sukhen C. Ghosh, Wei Xiong, Zhiqiang An, Qingyun Liu, and Kendra S. Carmon

1591 Secretory TRAIL-Armed Natural Killer Cell–Based Therapy: *In Vitro* and *In Vivo* Colorectal Peritoneal Carcinomatosis Xenograft

Xinxin Song, Se-Hoon Hong, William T. Kwon, Lisa M. Bailey, Per Basse, David L. Bartlett, YongTae Kwon, and Yong J. Lee

1602 Antagonists of IGF:Vitronectin Interactions Inhibit IGF-I–Induced Breast Cancer Cell Functions

Abhishek S. Kashyap, Gary K. Shooter, Ali Shokoohmand, Jacqui McGovern, Manaswini Sivaramakrishnan, Tristan I. Croll, Gaëlle Cane, David I. Leavesley, Ola Söderberg, Zee Upton, and Brett G. Hollier

1614 Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures

Ida Kjær, Trine Lindsted, Camilla Fröhlich, Jesper Velgaard Olsen, Ivan David Horak, Michael Kragh, and Mikkel Wandahl Pedersen

1656 MSK1-Mediated β -Catenin Phosphorylation Confers Resistance to PI3K/mTOR Inhibitors in Glioblastoma

Shaofang Wu, Shuzhen Wang, Siyuan Zheng, Roel Verhaak, Dimpy Koul, and W.K. Alfred Yung

1669 PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer

Ankita Jhuraney, Nicholas T. Woods, Gabriela Wright, Lily Rix, Fumi Kinose, Jodi L. Kroeger, Elizabeth Remily-Wood, W. Douglas Cress, John M. Koomen, Stephen G. Brantley, Jhanelle E. Gray, Eric B. Haura, Uwe Rix, and Alvaro N. Monteiro

1682 Cell-Cycle Gene Alterations in 4,864 Tumors Analyzed by Next-Generation Sequencing: Implications for Targeted Therapeutics



Teresa Helsten, Shumei Kato, Maria Schwaederle, Brett N. Tomson, Timon P.H. Buys, Sheryl K. Elkin, Jennifer L. Carter, and Razelle Kurzrock

1691 Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth *In Vitro* and *In Vivo*, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel

Xianzhe Liu, Yan Gao, Jacson Shen, Wen Yang, Edwin Choy, Henry Mankin, Francis J. Hornicek, and Zhenfeng Duan

1702 The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide

Stefan Prekovic, Martin E. van Royen, Arnout R.D. Voet, Bart Geverts, Rene Houtman, Diana Melchers, Kam Y.J. Zhang, Thomas Van den Broeck, Elien Smeets, Lien Spans, Adriaan B. Houtsmuller, Steven Joniau, Frank Claessens, and Christine Helsen

1713 Loss of PKC δ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/ β -Catenin Pathway and Mcl-1 Accumulation

M. Luz Flores, Carolina Castilla, Jessica Gasca, Rafael Medina, Begoña Pérez-Valderrama, Francisco Romero, Miguel A. Japón, and Carmen Sáez

CANCER BIOLOGY AND SIGNAL TRANSDUCTION

1627 EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines

Sung-Moo Kim, Hwan Kim, Kang Won Jang, Min Hwan Kim, Jinyoung Sohn, Mi Ran Yun, Han Na Kang, Chan Woo Kang, Hye Ryun Kim, Sun Min Lim, Yong Wha Moon, Joo Hang Kim, Soonmyung Paik, and Byoung Chul Cho



Table of Contents

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

1726 **Activating Transcription Factor 3 Expression as a Marker of Response to the Histone Deacetylase Inhibitor Pracinostat**

Dhanya Sooraj, Dakang Xu, Jason E. Cain, Daniel P. Gold, and Bryan R.G. Williams

1740 **Clinical Significance of *TLR1* I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab**

Satoshi Okazaki, Fotios Loupakis, Sebastian Stintzing, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Stefan Stremitzer, Satoshi Matsusaka, Martin D. Berger, Anish Parekh, Jordan D. West, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Chiara Cremolini, Alfredo Falcone, Volker Heinemann, R. William DePaolo, and Heinz-Josef Lenz

1746 **Genomic and Immunological Tumor Profiling Identifies Targetable Pathways and Extensive CD8⁺/PDL1⁺ Immune Infiltration in Inflammatory Breast Cancer Tumors**

Christopher A. Hamm, Diarmuid Moran, Kakuturu Rao, Patricia B. Trusk, Karen Pry, Mark Sausen, Siân Jones, Victor E. Velculescu, Massimo Cristofanilli, and Sarah Bacus

1757 **NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer**

Long-Shan Li, Srilakshmi Reddy, Zhen-Hua Lin, Shuangping Liu, Hyunsil Park, Stephen G. Chun, William G. Bornmann, Joel Thibodeaux, Jingsheng Yan, Gaurab Chakrabarti, Xian-Jin Xie, Baran D. Sumer, David A. Boothman, and John S. Yordy

1768 **Chromatin Regulators as a Guide for Cancer Treatment Choice**



Zachary A. Gurard-Levin, Laurence O.W. Wilson, Vera Pancaldi, Sophie Postel-Vinay, Fabricio G. Sousa, Cecile Reyes, Elisabetta Marangoni, David Gentien, Alfonso Valencia, Yves Pommier, Paul Cottu, and Geneviève Almouzni




AC icon indicates Author Choice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows the schematic of liposomal formulations for single drug-loaded nanoparticles of doxorubicin and carfilzomib (top and middle, respectively) and the carfilzomib and doxorubicin dual-loaded combination nanoparticle (bottom). Doxorubicin was chemically conjugated to a phospholipid via a labile hydrazone bond, while carfilzomib was passively loaded into the lipid bilayer. The dual drug-loaded combination nanoparticle demonstrated synergy *in vitro* and was more efficacious in inhibiting tumor growth *in vivo* than a combination of free drugs or single-agent liposomes. For more information, see the article by Ashley and colleagues beginning on page 1452.



Molecular Cancer Therapeutics

15 (7)

Mol Cancer Ther 2016;15:1425-1777.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/15/7>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/15/7>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.